title: [Successful induction of complete cytogenetic response with high-dose imatinib mesylate and subsequent allogeneic stem cell transplantation for CML blastic crisis].
abstract: A 29-year-old man was referred to our hospital with leukocytosis on March 7th, 2002. The white blood cell count was 132.9 x 10(3)/microliter with 42.0% blast cells. We diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in a blast crisis and started imatinib mesylate therapy at a dose of 800 mg/day on March 9th, 2002. The patient's peripheral blood blasts had disappeared by March 22nd, 2002, and the percentage of blasts in the bone marrow was 0.6% on May 2nd, 2002. The patient achieved a complete cytogenetic response on May 13th, 2002, and underwent allogeneic peripheral blood stem cell transplantation from his HLA-identical sibling donor on May 30th, 2002. Although adverse reactions such as grade 3/4 of hematological events (leukopenia, anemia, thrombocytopenia and neutropenia) and grade 1/2 of non-hematological events (hyperbilirubinemia, dermatitis and edema) were observed, these adverse reactions were clinically managed. This case suggested the usefulness of imatinib mesylate in the management of the CML-associated blast crisis.
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, Jikei University School of Medicine.
authors.forename: Katsuki
authors.initials: K
authors.lastname: Sugiyama
authors.forename: Noriko
authors.initials: N
authors.lastname: Usui
authors.forename: Osamu
authors.initials: O
authors.lastname: Asai
authors.forename: Takeshi
authors.initials: T
authors.lastname: Saito
authors.forename: Shingo
authors.initials: S
authors.lastname: Yano
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Okawa
authors.forename: Shinobu
authors.initials: S
authors.lastname: Takahara
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takei
authors.forename: Shinji
authors.initials: S
authors.lastname: Uno
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Dobashi
authors.forename: Masayuki
authors.initials: M
authors.lastname: Kobayashi
mesh_terms: D000328:Adult; D001549:Benzamides; D001752:Blast Crisis / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000628:therapy*; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D020551:Pulse Therapy, Drug; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate